# 

*May 2017 Enquiries: Chris Pockett +44 1453 524133*

**Renishaw demonstrates bespoke implant expertise at 3D Printing in Medicine**

**Global engineering and healthcare technologies company,** [Renishaw](http://www.renishaw.com/en/1030.aspx)**, is attending the second annual International 3D Printing in Medicine Conference in Mainz, Germany from May 19th-20th. Renishaw will demonstrate the potential opportunities that additive manufacturing (AM) creates in craniomaxillofacial surgery, by exhibiting its custom-made implants and providing demonstrations of its new implant design software ADEPT.**

**Renishaw will also demonstrate its expertise in patient specific implants (PSIs) for craniomaxillofacial applications, and explain the benefits of a digital workflow. On stand number 6, visitors will be introduced to successful examples of where the company’s implant technology has been used to improve patient lives, including a recent case where Neurosurgeon Bartolom**é Oliver performed a craniectomy using parts manufactured by Renishaw on an AM250 metal 3D printing machine. The company will also present further cases with work from various surgeons including Shakir Mustafa and his work in [Nepal](http://www.renishaw.com/en/mission-to-nepal-surgical-education-and-innovation-in-disaster-affected-regions--39918).

**During the conference, Renishaw will provide demonstrations of its new award-winning software package, ADEPT, which enables the widespread use of 3D printing to produce bespoke maxillofacial implants by overcoming the current cost and efficiency barriers. ADEPT, the result of a collaborative project, draws on the academic and industrial expertise of several UK partners;** Renishaw, LPW Technology Ltd, the Abertawe Bro Morgannwg University Health Board and PDR located within Cardiff Metropolitan University.

**“3D printing is a rapidly growing technology in many areas of medicine, as it has the potential to improve efficiency, accuracy and ease of customisation,” explained Ed Littlewood, Marketing Manager of Renishaw’s Medical and Dental Products Division. “Since we presented at the first annual conference last year, we have seen a growing interest and awareness of additively manufactured bespoke implants. This is something Renishaw hopes to build on at the 2017 conference.”**

**“AM technology for patient specific implants offers potential benefits to the surgeon, hospital and most importantly the patient,” explained Amy Davey,** Reconstructive Scientist at North Bristol NHS Trust. “The implants can have a positive impact on hospitals, by improving patient outcomes and speeding up surgery.

“Demonstrating successful cases of additively manufactured patient specific implants will help open the industry’s eyes to the potential of AM technology, increasing uptake and improving clinical outcomes.”

Visitors to the stand will also be introduced to Renishaw’s ***neuromate***® stereotactic neurosurgical robot, which surgeons can use to decrease procedure time and increase safety in a number of neurosurgical procedures including Deep Brain Stimulation (DBS) and Stereoelectroencephalography (SEEG). Surgeons can program the robot to aid placement of devices accurately into the desired anatomical brain region.

**The conference is set to be held at the Electoral Palace in Mainz and brings together physicians, materials scientists and engineers to present the results of their research in medical 3D printing and additive manufacturing.**

**Renishaw is the only UK manufacturer of metal additive manufacturing machines. For more information on how clinicians can improve patient outcomes with additive manufacturing, visit** <http://www.renishaw.com/en/metal-3d-printing-for-healthcare--24226>

Ends 485 words

Notes to editors

UK-based Renishaw is a world leading engineering technologies company, supplying products used for applications as diverse as jet engine and wind turbine manufacture, through to dentistry and brain surgery. It has over 4,000 employees located in the 35 countries where it has wholly owned subsidiary operations.

For the year ended June 2016 Renishaw recorded sales of £436.6 million of which 95% was due to exports. The company’s largest markets are China, the USA, Japan and Germany.

Throughout its history Renishaw has made a significant commitment to research and development, with historically between 14 and 18% of annual sales invested in R&D and engineering. The majority of this R&D and manufacturing of the company’s products is carried out in the UK.

The Company’s success has been recognised with numerous international awards, including eighteen Queen’s Awards recognising achievements in technology, export and innovation.

Renishaw is listed on the London Stock Exchange (LSE:RSW) where it is a constituent of the FTSE 250, with a current valuation of around £1.8 billion.

Further information at [www.renishaw.com](http://www.renishaw.com)